Protocol 1: standard tirzepatide protocol Goal: Achieve 15-20% body weight reduction over 6-12 months Dose escalation: Weeks 1-4: 2.5mg subcutaneous injection once weekly Weeks 5-8: 5mg once weekly Weeks 9-12: 7.5mg once weekly (optional, can skip to 10mg) Weeks 13-16: 10mg once weekly Weeks 17-20: 12.5mg once weekly Week 21+: 15mg once weekly maintenance Administration: Inject subcutaneously in abdomen, thigh, or upper arm Rotate injection sites to prevent injection site reactions Best administered on the same day each week Store properly per tirzepatide storage requirements Nutritional support: Minimum 100-120g protein daily (see tirzepatide diet planning ) Avoid high-fat, greasy foods during escalation (check foods to avoid list ) Stay hydrated, minimum 64oz water daily Consider targeted supplementation including multivitamins, omega-3s, and B12 Expected timeline: Weeks 1-4: Appetite suppression begins, 1-3% weight loss Weeks 5-12: Noticeable results, 5-8% weight loss Weeks 13-24: Significant changes, 10-15% weight loss Weeks 25-52: Approaching maximum benefit, 15-20%+ weight loss Protocol 2: retatrutide research protocol Goal: Achieve 20-28% body weight reduction over 6-12 months Dose escalation: Weeks 1-4: 1mg subcutaneous injection once weekly Weeks 5-8: 2mg once weekly Weeks 9-12: 4mg once weekly Weeks 13-16: 8mg once weekly Week 17+: 12mg once weekly maintenance Administration: Inject subcutaneously following standard retatrutide injection technique Optimal injection sites described in the retatrutide injection site guide Store refrigerated, reconstituted vials have limited stability (see retatrutide shelf life ) Reconstitute with bacteriostatic water per reconstitution chart Important monitoring: Track resting heart rate weekly (the glucagon receptor can elevate HR) Monitor liver enzymes if MASLD is present Track body composition changes, not just scale weight Assess GI tolerance at each dose increase, slow escalation if needed Expected timeline: Weeks 1-4: Mild appetite effects at initiation dose Weeks 5-12: Progressive appetite suppression, 5-10% weight loss Weeks 13-24: Significant metabolic effects, 12-18% weight loss Weeks 25-48: Approaching maximum benefit, 20-28%+ weight loss Protocol 3: transitioning from tirzepatide to retatrutide Goal: Safely switch between compounds while maintaining weight loss momentum This protocol is specifically for researchers who have been on tirzepatide and want to transition to retatrutide, typically because of a plateau or desire for additional metabolic benefits
Versatile Applications: Our platform supports a broad range of delivery routes, including oral, transdermal, pulmonary, ocular, and wound care formulations
Understanding these mechanisms clarifies why combined supplementation often outperforms single-agent approaches and why consistent use over weeks to months is necessary to observe structural gains
GH-LNPs proved better for in vitro drug release and in vivo memory repair potential in isoproterenol-induced cognitive challenged adult wistar rats (176)
DHT BLOCKER WITH BIOTIN: DHT is a common factor in both male pattern baldness
IV drops may be one of the easiest methods to achieve a good skin quotient score, and those interested should check with their dermatologist before proceeding
